Catalent Pharma Solutions, a Somerset, New Jersey-based drug-delivery technology company has entered into a deal with Nemus Bioscience, a biopharmaceutical company headquartered in Costa Mesa, California, to advance development of a human-dosage suppository formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC), NB1222, a drug under development for treating and managing chemotherapy-induced nausea and vomiting

NB1222, also known as the prodrug, THC-valine-hemisuccinate, is synthetically manufactured not plant-dervied. Nemus is preparing to advance the candidate to human clinical trials.

Source: Nemus Bioscience